Sopharma AD Past Earnings Performance
Past criteria checks 2/6
Sopharma AD has been growing earnings at an average annual rate of 11.7%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 9.2% per year. Sopharma AD's return on equity is 10%, and it has net margins of 3.9%.
Key information
11.7%
Earnings growth rate
10.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 9.2% |
| Return on equity | 10.0% |
| Net Margin | 3.9% |
| Next Earnings Update | 30 Jan 2025 |
Recent past performance updates
Recent updates
Sopharma AD's (BUL:SFA) Problems Go Beyond Weak Profit
Sep 07
Here's Why Sopharma AD (BUL:SFA) Can Manage Its Debt Responsibly
Jun 02Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet
Apr 09Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth Watching
Feb 20How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?
Feb 05Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?
Jan 22Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet
Jan 06
Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three Years
Dec 22Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?
Dec 07Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?
Nov 19Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?
Jul 07Revenue & Expenses Breakdown
How Sopharma AD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,974 | 78 | 280 | 0 |
| 31 Mar 24 | 1,932 | 93 | 265 | 0 |
| 31 Dec 23 | 1,888 | 95 | 255 | 0 |
| 30 Sep 23 | 1,832 | 81 | 242 | 0 |
| 30 Jun 23 | 1,787 | 91 | 233 | 0 |
| 31 Mar 23 | 1,742 | 83 | 224 | 0 |
| 31 Dec 22 | 1,672 | 71 | 216 | 0 |
| 30 Sep 22 | 1,651 | 107 | 223 | 0 |
| 30 Jun 22 | 1,655 | 101 | 223 | 0 |
| 31 Mar 22 | 1,629 | 92 | 222 | 0 |
| 31 Dec 21 | 1,611 | 89 | 225 | 0 |
| 30 Sep 21 | 1,608 | 58 | 225 | 0 |
| 30 Jun 21 | 1,527 | 41 | 219 | 0 |
| 31 Mar 21 | 1,460 | 37 | 214 | 0 |
| 31 Dec 20 | 1,446 | 30 | 213 | 0 |
| 30 Sep 20 | 1,375 | 75 | 194 | 0 |
| 30 Jun 20 | 1,353 | 85 | 201 | 0 |
| 31 Mar 20 | 1,340 | 82 | 200 | 0 |
| 31 Dec 19 | 1,288 | 87 | 196 | 0 |
| 30 Sep 19 | 1,257 | 35 | 200 | 0 |
| 30 Jun 19 | 1,231 | 30 | 191 | 0 |
| 31 Mar 19 | 1,209 | 31 | 192 | 0 |
| 31 Dec 18 | 1,188 | 28 | 187 | 0 |
| 30 Sep 18 | 1,166 | 34 | 183 | 0 |
| 30 Jun 18 | 1,125 | 32 | 178 | 0 |
| 31 Mar 18 | 1,077 | 35 | 166 | 0 |
| 31 Dec 17 | 1,024 | 40 | 158 | 0 |
| 30 Sep 17 | 965 | 52 | 149 | 0 |
| 30 Jun 17 | 930 | 53 | 142 | 0 |
| 31 Mar 17 | 906 | 57 | 142 | 0 |
| 31 Dec 16 | 883 | 51 | 139 | 0 |
| 30 Sep 16 | 874 | 29 | 140 | 0 |
| 30 Jun 16 | 867 | 21 | 141 | 0 |
| 31 Mar 16 | 878 | 23 | 138 | 0 |
| 31 Dec 15 | 883 | 21 | 141 | 0 |
| 30 Sep 15 | 883 | 24 | 145 | 0 |
| 30 Jun 15 | 877 | 29 | 143 | 0 |
| 31 Mar 15 | 860 | 17 | 141 | 0 |
| 31 Dec 14 | 852 | 20 | 142 | 0 |
| 30 Sep 14 | 833 | 19 | 135 | 0 |
| 30 Jun 14 | 811 | 19 | 136 | 0 |
| 31 Mar 14 | 793 | 24 | 134 | 0 |
| 31 Dec 13 | 767 | 29 | 128 | 0 |
Quality Earnings: SFA has high quality earnings.
Growing Profit Margin: SFA's current net profit margins (3.9%) are lower than last year (5.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SFA's earnings have grown by 11.7% per year over the past 5 years.
Accelerating Growth: SFA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SFA had negative earnings growth (-14.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10.2%).
Return on Equity
High ROE: SFA's Return on Equity (10%) is considered low.